| Name | Talmapimod |
| Description | Talmapimod (SCIO-469) is a selective, orally active, ATP-competitive p38α inhibitor with IC50 values of 9 nM for p38α and 90 nM for p38β. Talmapimod exhibits at least 2000-fold selectivity over a panel of 20 kinases, including other MAPKs. |
| In vitro | phosphorylation of p38 MAPK inhibited by Talmapimod (100-200 nM; 1 hour) in MM cells[1].In human whole blood, LPS-induced TNF-a production inhibited by Talmapimod [2]. Talmapimod decreases constitutive p38alpha MAPK phosphorylation of both 5T2MM and 5T33MM cells[3]. |
| In vivo | Talmapimod (SCIO-469), targeting p38α MAPK, reduces myeloma burden and prevents myeloma bone disease[2]. In 5T2MM and 5T33MM models, it inhibits multiple myeloma growth and bone diseases[3]. Administered at 10-90 mg/kg orally, twice daily for 14 days, Talmapimod dose-dependently diminishes tumor growth and decreases the weight of palpable tumors at termination[4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 95 mg/mL (185.19 mM), Sonication is recommended.
|
| Keywords | tumor | Talmapimod | SCIO469 | SCIO 469 | phosphorylation | p38β | p38α | p38MAPK | p38 MAPK | myeloma | multiple | Inhibitor | inhibit | Hsp27 | cytotoxicity | cells |
| Inhibitors Related | Adezmapimod | Exarafenib | Doramapimod | VX-702 | Bakuchiol | p38α inhibitor 3 | SB 202190 | (-)-Bornyl acetate | MW-150 | (E)-Ferulic acid methyl ester | p38-α MAPK-IN-1 | Nisin Z |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
